2026 ASCO Annual Meeting

First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer

Oral |
Abstract

Saturday,
May 30

1:15 PM CDT

Prof. Rob Stein, M.B.B.S., Ph.D.
University College London, OPTIMA Trial Principal Investigator

Breast Cancer – Local/Regional/Adjuvant, Hall B1

Assessment of the ability of Decipher Prostate Genomic Classifier (GC) >0.85 to identify patients who benefit from adding docetaxel to Androgen Deprivation Therapy (ADT) plus enzalutamide: Level 1B evidence from the ENZAMET study.

Oral |
Abstract #5001

Saturday,
May 30

3:12 PM – 3:24 PM CDT

Christopher Sweeney, M.B.B.S.

Hall D1

Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521

Oral |
Abstract #5000

Saturday,
May 30

3:00 PM – 3:12 PM CDT

Krishnan R. Patel, M.D.

Hall D1

Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: a national real-world data analysis

Abstract #1660 |
Poster bd #578

Saturday,
May 30

9:00 AM – 12:00 PM CDT

James Janopaul-Naylor, M.D.

Hall A

Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial

Abstract #4619 |
Poster bd #98

Sunday,
May 31

9:00 AM – 12:00 PM CDT

Brigida A. Maiorano, M.D., Ph.D.

Hall A

Assessing the clinical and biological associations between artera Multimodal Artificial Intelligence (MMAI) and Decipher Genomic Classifier (GC) in Localized Prostate Cancer (PCa)

Abstract #5114 |
Poster bd #209

Sunday,
May 31

9:00 AM – 12:00 PM CDT

Boon Hao Hong, MS

Hall A

Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC)

Abstract #4617 |
Poster bd #96

Sunday,
May 31

9:00 AM – 12:00 PM CDT

Andrea Necchi, M.D.

Hall A

Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer.

Rapid Oral |
Abstract #5013

Sunday,
May 31

4:36 PM – 4:42 PM CDT

Daniel Keizman, M.D.

Hall D1